Allergan Inc. (AGN) Issues FY14 Earnings Guidance
Allergan Inc. (NYSE:AGN) updated its FY14 earnings guidance on Wednesday. The company provided earnings per share guidance of $5.36-5.48 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.46, American Banking and Market News reports. The company issued revenue guidance of $6.65-6.95 billion, compared to the consensus revenue estimate of $6.87 billion.Allergan also updated its Q1 guidance to $1.09-1.12 EPS.
A number of research firms have recently commented on AGN. Analysts at Citigroup Inc. upgraded shares of Allergan from a neutral rating to a buy rating in a research note to investors on Tuesday. They now have a $130.00 price target on the stock, up previously from $95.00. On a related note, analysts at SunTrust upgraded shares of Allergan from a neutral rating to a buy rating in a research note to investors on Friday, January 17th. They now have a $150.00 price target on the stock, up previously from $94.00. Finally, analysts at Morgan Stanley reiterated an equal weight rating on shares of Allergan in a research note to investors on Wednesday, January 15th. They now have a $94.00 price target on the stock. Seven investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. The company presently has an average rating of Buy and a consensus price target of $116.86.
Allergan Inc. (NYSE:AGN) traded up 0.17% on Wednesday, hitting $114.88. The stock had a trading volume of 2,287,897 shares. Allergan Inc. has a 1-year low of $81.33 and a 1-year high of $123.83. The stock has a 50-day moving average of $112.9 and a 200-day moving average of $96.91. The company has a market cap of $34.138 billion and a P/E ratio of 34.77.
Allergan (NYSE:AGN) last issued its quarterly earnings data on Tuesday, February 4th. The company reported $1.12 earnings per share for the quarter, missing the analysts’ consensus estimate of $1.34 by $0.22. The company had revenue of $1.66 million for the quarter, compared to the consensus estimate of $1.65 million. During the same quarter last year, the company posted $1.15 earnings per share. Allergan’s revenue was up 14.4% compared to the same quarter last year. Analysts expect that Allergan Inc. will post $4.76 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which is scheduled for Friday, March 21st. Stockholders of record on Friday, February 28th will be paid a dividend of 0.05 per share. This represents a $0.20 annualized dividend and a dividend yield of 0.17%.
Allergan, Inc, is a multi-specialty health care company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.